
Genmab Announces Financial Results for the First Quarter of 2024
The U.S. Food and Drug Administration (U.S. FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) aimed at treating adult patients with relapsed or…












